Transcriptional and Splicing Regulation of Spinal Muscular Atrophy Genes

Spinal Muscular Atrophy: Disease Mechanisms and Therapy

Volumn , Issue , 2017, Pages 75-97

  Singh, N N ^a   Howell, M D ^a   Singh, R N ^a  

^a IOWA STATE UNIVERSITY   (United States)

Author keywords

Element 1; GCRS; ISS N1; ISS N2; ISTL1; SMA; SMN; Splicing

Indexed keywords

EID: 85026917797     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-803685-3.00005-7     Document Type: Chapter

References (170)

1. Prior T.W. Spinal muscular atrophy diagnostics. J Child Neurol 2007, 22(8):952-956. http://dx.doi.org/10.1177/0883073807305668.
2. Kolb S.J., Kissel J.T. Spinal muscular atrophy: a timely review. Arch Neurol 2011, 68(8):979-984. http://dx.doi.org/10.1001/archneurol.2011.74.
3. Tiziano F.D., Melki J., Simard L.R. Solving the puzzle of spinal muscular atrophy: what are the missing pieces?. Am J Med Genet A 2013, 161A(11):2836-2845. http://dx.doi.org/10.1002/ajmg.a.36251.
4. Awano T., Kim J.-K., Monani U.R. Spinal muscular atrophy: journeying from bench to bedside. Neurotherapeutics 2014, 11(4):786-795. http://dx.doi.org/10.1007/s13311-014-0293-y.
5. Lefebvre S., Bürglen L., Reboullet S., et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995, 80(1):155-165.
6. Bürglen L., Lefebvre S., Clermont O., et al. Structure and organization of the human survival motor neurone (SMN) gene. Genomics 1996, 32(3):479-482. http://dx.doi.org/10.1006/geno.1996.0147.
7. McAndrew P.E., Parsons D.W., Simard L.R., et al. Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am J Hum Genet 1997, 60(6):1411-1422. http://dx.doi.org/10.1086/515465.
8. Wee C.D., Kong L., Sumner C.J. The genetics of spinal muscular atrophies. Curr Opin Neurol 2010, 23(5):450-458. http://dx.doi.org/10.1097/WCO.0b013e32833e1765.
9. Battle D.J., Kasim M., Yong J., et al. The SMN complex: an assembly machine for RNPs. Cold Spring Harb Symp Quant Biol 2006, 71:313-320. http://dx.doi.org/10.1101/sqb.2006.71.001.
10. Winkler C., Eggert C., Gradl D., et al. Reduced U snRNP assembly causes motor axon degeneration in an animal model for spinal muscular atrophy. Genes Dev 2005, 19(19):2320-2330. http://dx.doi.org/10.1101/gad.342005.
11. Strasswimmer J., Lorson C.L., Breiding D.E., et al. Identification of survival motor neuron as a transcriptional activator-binding protein. Hum Mol Genet 1999, 8(7):1219-1226.
12. Rossoll W., Kröning A.-K., Ohndorf U.-M., Steegborn C., Jablonka S., Sendtner M. Specific interaction of Smn, the spinal muscular atrophy determining gene product, with hnRNP-R and gry-rbp/hnRNP-Q: a role for Smn in RNA processing in motor axons?. Hum Mol Genet 2002, 11(1):93-105.
13. Bowerman M., Shafey D., Kothary R. Smn depletion alters profilin II expression and leads to upregulation of the RhoA/ROCK pathway and defects in neuronal integrity. J Mol Neurosci 2007, 32(2):120-131.
14. Peter C.J., Evans M., Thayanithy V., et al. The COPI vesicle complex binds and moves with survival motor neuron within axons. Hum Mol Genet 2011, 20(9):1701-1711. http://dx.doi.org/10.1093/hmg/ddr046.
15. Fallini C., Zhang H., Su Y., et al. The survival of motor neuron (SMN) protein interacts with the mRNA-binding protein HuD and regulates localization of poly(A) mRNA in primary motor neuron axons. J Neurosci 2011, 31(10):3914-3925. http://dx.doi.org/10.1523/JNEUROSCI.3631-10.2011.
16. Zou T., Yang X., Pan D., Huang J., Sahin M., Zhou J. SMN deficiency reduces cellular ability to form stress granules, sensitizing cells to stress. Cell Mol Neurobiol 2011, 31(4):541-550. http://dx.doi.org/10.1007/s10571-011-9647-8.
17. Jodelka F.M., Ebert A.D., Duelli D.M., Hastings M.L. A feedback loop regulates splicing of the spinal muscular atrophy-modifying gene, SMN2. Hum Mol Genet 2010, 19(24):4906-4917. http://dx.doi.org/10.1093/hmg/ddq425.
18. Sanchez G., Dury A.Y., Murray L.M., et al. A novel function for the survival motoneuron protein as a translational regulator. Hum Mol Genet 2013, 22(4):668-684. http://dx.doi.org/10.1093/hmg/dds474.
19. Takaku M., Tsujita T., Horikoshi N., et al. Purification of the human SMN-GEMIN2 complex and assessment of its stimulation of RAD51-mediated DNA recombination reactions. Biochemistry 2011, 50(32):6797-6805. http://dx.doi.org/10.1021/bi200828g.
20. Praveen K., Wen Y., Matera A.G. A Drosophila model of spinal muscular atrophy uncouples snRNP biogenesis functions of survival motor neuron from locomotion and viability defects. Cell Rep 2012, 1(6):624-631. http://dx.doi.org/10.1016/j.celrep.2012.05.014.
21. Lorson C.L., Hahnen E., Androphy E.J., Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 1999, 96(11):6307-6311.
22. Monani U.R., Lorson C.L., Parsons D.W., et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet 1999, 8(7):1177-1183.
23. Burnett B.G., Muñoz E., Tandon A., Kwon D.Y., Sumner C.J., Fischbeck K.H. Regulation of SMN protein stability. Mol Cell Biol 2009, 29(5):1107-1115. http://dx.doi.org/10.1128/MCB.01262-08.
24. Cho S., Dreyfuss G. A degron created by SMN2 exon 7 skipping is a principal contributor to spinal muscular atrophy severity. Genes Dev 2010, 24(5):438-442. http://dx.doi.org/10.1101/gad.1884910.
25. Schrank B., Götz R., Gunnersen J.M., et al. Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci USA 1997, 94(18):9920-9925.
26. -/- mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet 2000, 9(3):333-339.
27. Chen H.-H., Chang J.-G., Lu R.-M., Peng T.-Y., Tarn W.-Y. The RNA binding protein hnRNP Q modulates the utilization of exon 7 in the survival motor neuron 2 (SMN2). Gene Mol Cell Biol 2008, 28(22):6929-6938. http://dx.doi.org/10.1128/MCB.01332-08.
28. Chen Y.-C., Chang J.-G., Jong Y.-J., Liu T.-Y., Yuo C.-Y. High expression level of Tra2-β1 is responsible for increased SMN2 exon 7 inclusion in the testis of SMA mice. PLoS One 2015, 10(3):e0120721. http://dx.doi.org/10.1371/journal.pone.0120721.
29. Sivanesan S., Howell M.D., DiDonato C.J., Singh R.N. Antisense oligonucleotide mediated therapy of spinal muscular atrophy. Transl Neurosci 2013, 4(1):1-7. http://dx.doi.org/10.2478/s13380-013-0109-2.
30. Porensky P.N., Burghes A.H.M. Antisense oligonucleotides for the treatment of spinal muscular atrophy. Hum Gene Ther 2013, 24(5):489-498. http://dx.doi.org/10.1089/hum.2012.225.
31. Rigo F., Seth P.P., Bennett C.F. Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects. Adv Exp Med Biol 2014, 825:303-352. http://dx.doi.org/10.1007/978-1-4939-1221-6_9.
32. Singh N.N., Lee B.M., DiDonato C.J., Singh R.N. Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy. Future Med Chem 2015, 7(13):1793-1808. http://dx.doi.org/10.4155/fmc.15.101.
33. Park G.-H., Kariya S., Monani U.R. Spinal muscular atrophy: new and emerging insights from model mice. Curr Neurol Neurosci Rep 2010, 10(2):108-117. http://dx.doi.org/10.1007/s11910-010-0095-5.
34. Le T.T., Pham L.T., Butchbach M.E.R., et al. SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet 2005, 14(6):845-857. http://dx.doi.org/10.1093/hmg/ddi078.
35. Chang J.G., Hsieh-Li H.M., Jong Y.J., Wang N.M., Tsai C.H., Li H. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA 2001, 98(17):9808-9813. http://dx.doi.org/10.1073/pnas.171105098.
36. Avila A.M., Burnett B.G., Taye A.A., et al. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest 2007, 117(3):659-671. http://dx.doi.org/10.1172/JCI29562.
37. Riessland M., Ackermann B., Förster A., et al. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Hum Mol Genet 2010, 19(8):1492-1506. http://dx.doi.org/10.1093/hmg/ddq023.
38. Van Meerbeke J.P., Gibbs R.M., Plasterer H.L., et al. The DcpS inhibitor RG3039 improves motor function in SMA mice. Hum Mol Genet 2013, 22(20):4074-4083. http://dx.doi.org/10.1093/hmg/ddt257.
39. Bentley D.L. Coupling mRNA processing with transcription in time and space. Nat Rev Genet 2014, 15(3):163-175. http://dx.doi.org/10.1038/nrg3662.
40. Muñoz M.J., de la Mata M., Kornblihtt A.R. The carboxy terminal domain of RNA polymerase II and alternative splicing. Trends Biochem Sci 2010, 35(9):497-504. http://dx.doi.org/10.1016/j.tibs.2010.03.010.
41. Rigo F., Martinson H.G. Polyadenylation releases mRNA from RNA polymerase II in a process that is licensed by splicing. RNA 2009, 15(5):823-836. http://dx.doi.org/10.1261/rna.1409209.
42. Mapendano C.K., Lykke-Andersen S., Kjems J., Bertrand E., Jensen T.H. Crosstalk between mRNA 3' end processing and transcription initiation. Mol Cell 2010, 40(3):410-422. http://dx.doi.org/10.1016/j.molcel.2010.10.012.
43. Pawlicki J.M., Steitz J.A. Nuclear networking fashions pre-messenger RNA and primary microRNA transcripts for function. Trends Cell Biol 2010, 20(1):52-61. http://dx.doi.org/10.1016/j.tcb.2009.10.004.
44. Ip J.Y., Schmidt D., Pan Q., et al. Global impact of RNA polymerase II elongation inhibition on alternative splicing regulation. Genome Res 2011, 21(3):390-401. http://dx.doi.org/10.1101/gr.111070.110.
45. de Klerk E., Hoen P.A.C. Alternative mRNA transcription, processing, and translation: insights from RNA sequencing. Trends Genet 2015, 31(3):128-139. http://dx.doi.org/10.1016/j.tig.2015.01.001.
46. Jonkers I., Lis J.T. Getting up to speed with transcription elongation by RNA polymerase II. Nat Rev Mol Cell Biol 2015, 16(3):167-177. http://dx.doi.org/10.1038/nrm3953.
47. Burghes A.H.M., Beattie C.E. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?. Nat Rev Neurosci 2009, 10(8):597-609. http://dx.doi.org/10.1038/nrn2670.
48. Lorson C.L., Rindt H., Shababi M. Spinal muscular atrophy: mechanisms and therapeutic strategies. Hum Mol Genet 2010, 19(R1):R111-R118. http://dx.doi.org/10.1093/hmg/ddq147.
49. Bebee T.W., Gladman J.T., Chandler D.S. Splicing regulation of the survival motor neuron genes and implications for treatment of spinal muscular atrophy. Front Biosci (Landmark Ed) 2010, 15:1191-1204.
50. Shababi M., Mattis V.B., Lorson C.L. Therapeutics that directly increase SMN expression to treat spinal muscular atrophy. Drug News Perspect 2010, 23(8):475-482. http://dx.doi.org/10.1358/dnp.2010.23.8.1507295.
51. Seo J., Howell M.D., Singh N.N., Singh R.N. Spinal muscular atrophy: an update on therapeutic progress. Biochim Biophys Acta 2013, 1832(12):2180-2190. http://dx.doi.org/10.1016/j.bbadis.2013.08.005.
52. Nurputra D.K., Lai P.S., Harahap N.I.F., et al. Spinal muscular atrophy: from gene discovery to clinical trials. Ann Hum Genet 2013, 77(5):435-463. http://dx.doi.org/10.1111/ahg.12031.
53. Howell M.D., Singh N.N., Singh R.N. Advances in therapeutic development for spinal muscular atrophy. Future Med Chem 2014, 6(9):1081-1099. http://dx.doi.org/10.4155/fmc.14.63.
54. Rochette C.F., Gilbert N., Simard L.R. SMN gene duplication and the emergence of the SMN2 gene occurred in distinct hominids: SMN2 is unique to Homo sapiens. Hum Genet 2001, 108(3):255-266.
55. Singh N.N., Seo J., Rahn S.J., Singh R.N. A multi-exon-skipping detection assay reveals surprising diversity of splice isoforms of spinal muscular atrophy genes. PLoS One 2012, 7(11):e49595. http://dx.doi.org/10.1371/journal.pone.0049595.
56. Hsieh-Li H.M., Chang J.G., Jong Y.J., et al. A mouse model for spinal muscular atrophy. Nat Genet 2000, 24(1):66-70. http://dx.doi.org/10.1038/71709.
57. Setola V., Terao M., Locatelli D., Bassanini S., Garattini E., Battaglia G. Axonal-SMN (a-SMN), a protein isoform of the survival motor neuron gene, is specifically involved in axonogenesis. PNAS 2007, 104(6):1959-1964. http://dx.doi.org/10.1073/pnas.0610660104.
58. Locatelli D., Terao M., Fratelli M., et al. Human axonal survival of motor neuron (a-SMN) protein stimulates axon growth, cell motility, C-C motif ligand 2 (CCL2), and insulin-like growth factor-1 (IGF1) production. J Biol Chem 2012, 287(31):25782-25794. http://dx.doi.org/10.1074/jbc.M112.362830.
59. Nguyen L.S., Wilkinson M.F., Gecz J. Nonsense-mediated mRNA decay: inter-individual variability and human disease. Neurosci Biobehav Rev 2014, 46(Pt 2):175-186. http://dx.doi.org/10.1016/j.neubiorev.2013.10.016.
60. Locatelli D., Terao M., Kurosaki M., et al. Different stability and proteasome-mediated degradation rate of SMN protein isoforms. PLoS One 2015, 10(7):e0134163. http://dx.doi.org/10.1371/journal.pone.0134163.
61. Silva A.L., Romão L. The mammalian nonsense-mediated mRNA decay pathway: to decay or not to decay! Which players make the decision?. FEBS Lett 2009, 583(3):499-505. http://dx.doi.org/10.1016/j.febslet.2008.12.058.
62. Wang Z., Burge C.B. Splicing regulation: from a parts list of regulatory elements to an integrated splicing code. RNA 2008, 14(5):802-813. http://dx.doi.org/10.1261/rna.876308.
63. Wang E.T., Sandberg R., Luo S., et al. Alternative isoform regulation in human tissue transcriptomes. Nature 2008, 456(7221):470-476. http://dx.doi.org/10.1038/nature07509.
64. Yu Y., Maroney P.A., Denker J.A., et al. Dynamic regulation of alternative splicing by silencers that modulate 5' splice site competition. Cell 2008, 135(7):1224-1236. http://dx.doi.org/10.1016/j.cell.2008.10.046.
65. Barash Y., Calarco J.A., Gao W., et al. Deciphering the splicing code. Nature 2010, 465(7294):53-59. http://dx.doi.org/10.1038/nature09000.
66. Xiong H.Y., Alipanahi B., Lee L.J., et al. RNA splicing. The human splicing code reveals new insights into the genetic determinants of disease. Science 2015, 347(6218):1254806. http://dx.doi.org/10.1126/science.1254806.
67. Lim S.R., Hertel K.J. Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3' splice site pairing. J Biol Chem 2001, 276(48):45476-45483. http://dx.doi.org/10.1074/jbc.M107632200.
68. Cartegni L., Krainer A.R. Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet 2002, 30(4):377-384. http://dx.doi.org/10.1038/ng854.
69. Kashima T., Manley J.L. A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat Genet 2003, 34(4):460-463. http://dx.doi.org/10.1038/ng1207.
70. Singh N.N., Androphy E.J., Singh R.N. In vivo selection reveals combinatorial controls that define a critical exon in the spinal muscular atrophy genes. RNA 2004, 10(8):1291-1305. http://dx.doi.org/10.1261/rna.7580704.
71. Singh N.N., Singh R.N., Androphy E.J. Modulating role of RNA structure in alternative splicing of a critical exon in the spinal muscular atrophy genes. Nucleic Acids Res 2007, 35(2):371-389. http://dx.doi.org/10.1093/nar/gkl1050.
72. Singh N.N., Lee B.M., Singh R.N. Splicing regulation in spinal muscular atrophy by an RNA structure formed by long-distance interactions. Ann NY Acad Sci 2015, 1341:176-187. http://dx.doi.org/10.1111/nyas.12727.
73. Cléry A., Jayne S., Benderska N., Dominguez C., Stamm S., Allain F.H.-T. Molecular basis of purine-rich RNA recognition by the human SR-like protein Tra2-β1. Nat Struct Mol Biol 2011, 18(4):443-450. http://dx.doi.org/10.1038/nsmb.2001.
74. Singh N.N., Seo J., Ottesen E.W., Shishimorova M., Bhattacharya D., Singh R.N. TIA1 prevents skipping of a critical exon associated with spinal muscular atrophy. Mol Cell Biol 2011, 31(5):935-954. http://dx.doi.org/10.1128/MCB.00945-10.
75. Singh N.N., Lawler M.N., Ottesen E.W., Upreti D., Kaczynski J.R., Singh R.N. An intronic structure enabled by a long-distance interaction serves as a novel target for splicing correction in spinal muscular atrophy. Nucleic Acids Res 2013, 41(17):8144-8165. http://dx.doi.org/10.1093/nar/gkt609.
76. Kashima T., Rao N., Manley J.L. An intronic element contributes to splicing repression in spinal muscular atrophy. Proc Natl Acad Sci USA 2007, 104(9):3426-3431. http://dx.doi.org/10.1073/pnas.0700343104.
77. Doktor T.K., Schroeder L.D., Vested A., et al. SMN2 exon 7 splicing is inhibited by binding of hnRNP A1 to a common ESS motif that spans the 3' splice site. Hum Mutat 2011, 32(2):220-230. http://dx.doi.org/10.1002/humu.21419.
78. Hua Y., Vickers T.A., Okunola H.L., Bennett C.F., Krainer A.R. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet 2008, 82(4):834-848. http://dx.doi.org/10.1016/j.ajhg.2008.01.014.
79. Singh N.N., Androphy E.J., Singh R.N. An extended inhibitory context causes skipping of exon 7 of SMN2 in spinal muscular atrophy. Biochem Biophys Res Commun 2004, 315(2):381-388. http://dx.doi.org/10.1016/j.bbrc.2004.01.067.
80. Pedrotti S., Bielli P., Paronetto M.P., et al. The splicing regulator Sam68 binds to a novel exonic splicing silencer and functions in SMN2 alternative splicing in spinal muscular atrophy. EMBO J 2010, 29(7):1235-1247. http://dx.doi.org/10.1038/emboj.2010.19.
81. Hofmann Y., Lorson C.L., Stamm S., Androphy E.J., Wirth B. Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). Proc Natl Acad Sci USA 2000, 97(17):9618-9623. http://dx.doi.org/10.1073/pnas.160181697.
82. Hofmann Y., Wirth B. hnRNP-G promotes exon 7 inclusion of survival motor neuron (SMN) via direct interaction with Htra2-beta1. Hum Mol Genet 2002, 11(17):2037-2049.
83. Young P.J., DiDonato C.J., Hu D., Kothary R., Androphy E.J., Lorson C.L. SRp30c-dependent stimulation of survival motor neuron (SMN) exon 7 inclusion is facilitated by a direct interaction with hTra2 beta 1. Hum Mol Genet 2002, 11(5):577-587.
84. Moursy A., Allain F.H.-T., Cléry A. Characterization of the RNA recognition mode of hnRNP G extends its role in SMN2 splicing regulation. Nucleic Acids Res 2014, 42(10):6659-6672. http://dx.doi.org/10.1093/nar/gku244.
85. Bose J.K., Wang I.-F., Hung L., Tarn W.-Y., Shen C.-K.J. TDP-43 overexpression enhances exon 7 inclusion during the survival of motor neuron pre-mRNA splicing. J Biol Chem 2008, 283(43):28852-28859. http://dx.doi.org/10.1074/jbc.M805376200.
86. Mende Y., Jakubik M., Riessland M., et al. Deficiency of the splicing factor Sfrs10 results in early embryonic lethality in mice and has no impact on full-length SMN/Smn splicing. Hum Mol Genet 2010, 19(11):2154-2167. http://dx.doi.org/10.1093/hmg/ddq094.
87. Cho S., Moon H., Loh T.J., et al. PSF contacts exon 7 of SMN2 pre-mRNA to promote exon 7 inclusion. Biochim Biophys Acta 2014, 1839(6):517-525. http://dx.doi.org/10.1016/j.bbagrm.2014.03.003.
88. Cho S., Moon H., Loh T.J., et al. hnRNP M facilitates exon 7 inclusion of SMN2 pre-mRNA in spinal muscular atrophy by targeting an enhancer on exon 7. Biochim Biophys Acta 2014, 1839(4):306-315. http://dx.doi.org/10.1016/j.bbagrm.2014.02.006.
89. Vezain M., Saugier-Veber P., Goina E., et al. A rare SMN2 variant in a previously unrecognized composite splicing regulatory element induces exon 7 inclusion and reduces the clinical severity of spinal muscular atrophy. Hum Mutat 2010, 31(1):E1110-E1125. http://dx.doi.org/10.1002/humu.21173.
90. Bernal S., Alías L., Barceló M.J., et al. The c.859G>C variant in the SMN2 gene is associated with types II and III SMA and originates from a common ancestor. J Med Genet 2010, 47(9):640-642. http://dx.doi.org/10.1136/jmg.2010.079004.
91. Singh N.N., Androphy E.J., Singh R.N. The regulation and regulatory activities of alternative splicing of the SMN gene. Crit Rev Eukaryot Gene Expr 2004, 14(4):271-285.
92. Singh R.N. Unfolding the mystery of alternative splicing through a unique method of in vivo selection. Front Biosci 2007, 12:3263-3272.
93. Singh R.N. Evolving concepts on human SMN pre-mRNA splicing. RNA Biol 2007, 4(1):7-10.
94. Hua Y., Vickers T.A., Baker B.F., Bennett C.F., Krainer A.R. Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol 2007, 5(4):e73. http://dx.doi.org/10.1371/journal.pbio.0050073.
95. Gladman J.T., Bebee T.W., Edwards C., et al. A humanized Smn gene containing the SMN2 nucleotide alteration in exon 7 mimics SMN2 splicing and the SMA disease phenotype. Hum Mol Genet 2010, 19(21):4239-4252. http://dx.doi.org/10.1093/hmg/ddq343.
96. Palacino J., Swalley S.E., Song C., et al. SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice. Nat Chem Biol 2015, 11(7):511-517. http://dx.doi.org/10.1038/nchembio.1837.
97. Miyajima H., Miyaso H., Okumura M., Kurisu J., Imaizumi K. Identification of a cis-acting element for the regulation of SMN exon 7 splicing. J Biol Chem 2002, 277(26):23271-23277. http://dx.doi.org/10.1074/jbc.M200851200.
98. Baughan T.D., Dickson A., Osman E.Y., Lorson C.L. Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy. Hum Mol Genet 2009, 18(9):1600-1611. http://dx.doi.org/10.1093/hmg/ddp076.
99. Singh N.K., Singh N.N., Androphy E.J., Singh R.N. Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol 2006, 26(4):1333-1346. http://dx.doi.org/10.1128/MCB.26.4.1333-1346.2006.
100. Rigo F., Chun S.J., Norris D.A., et al. Pharmacology of a central nervous system delivered 2'-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates. J Pharmacol Exp Ther 2014, 350(1):46-55. http://dx.doi.org/10.1124/jpet.113.212407.
101. Singh N.N., Hollinger K., Bhattacharya D., Singh R.N. An antisense microwalk reveals critical role of an intronic position linked to a unique long-distance interaction in pre-mRNA splicing. RNA 2010, 16(6):1167-1181. http://dx.doi.org/10.1261/rna.2154310.
102. Singh N.N., Shishimorova M., Cao L.C., Gangwani L., Singh R.N. A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy. RNA Biol 2009, 6(3):341-350.
103. Keil J.M., Seo J., Howell M.D., Hsu W.H., Singh R.N., DiDonato C.J. A short antisense oligonucleotide ameliorates symptoms of severe mouse models of spinal muscular atrophy. Mol Ther Nucleic Acids 2014, 3:e174. http://dx.doi.org/10.1038/mtna.2014.23.
104. Miyaso H., Okumura M., Kondo S., Higashide S., Miyajima H., Imaizumi K. An intronic splicing enhancer element in survival motor neuron (SMN) pre-mRNA. J Biol Chem 2003, 278(18):15825-15831. http://dx.doi.org/10.1074/jbc.M209271200.
105. Aznarez I., Barash Y., Shai O., et al. A systematic analysis of intronic sequences downstream of 5' splice sites reveals a widespread role for U-rich motifs and TIA1/TIAL1 proteins in alternative splicing regulation. Genome Res 2008, 18(8):1247-1258. http://dx.doi.org/10.1101/gr.073155.107.
106. Klar J., Sobol M., Melberg A., et al. Welander distal myopathy caused by an ancient founder mutation in TIA1 associated with perturbed splicing. Hum Mutat 2013, 34(4):572-577. http://dx.doi.org/10.1002/humu.22282.
107. Wee C.D., Havens M.A., Jodelka F.M., Hastings M.L. Targeting SR proteins improves SMN expression in spinal muscular atrophy cells. PLoS One 2014, 9(12):e115205. http://dx.doi.org/10.1371/journal.pone.0115205.
108. Irimura S., Kitamura K., Kato N., et al. HnRNP C1/C2 may regulate exon 7 splicing in the spinal muscular atrophy gene SMN1. Kobe J Med Sci 2009, 54(5):E227-E236.
109. Cartegni L., Hastings M.L., Calarco J.A., de Stanchina E., Krainer A.R. Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. Am J Hum Genet 2006, 78(1):63-77. http://dx.doi.org/10.1086/498853.
110. Kashima T., Rao N., David C.J., Manley J.L. hnRNP A1 functions with specificity in repression of SMN2 exon 7 splicing. Hum Mol Genet 2007, 16(24):3149-3159. http://dx.doi.org/10.1093/hmg/ddm276.
111. Xiao R., Tang P., Yang B., et al. Nuclear matrix factor hnRNP U/SAF-A exerts a global control of alternative splicing by regulating U2 snRNP maturation. Mol Cell 2012, 45(5):656-668. http://dx.doi.org/10.1016/j.molcel.2012.01.009.
112. Li J., Chen X., Xiao P., et al. Expression pattern and splicing function of mouse ZNF265. Neurochem Res 2008, 33(3):483-489. http://dx.doi.org/10.1007/s11064-007-9461-3.
113. Heinrich B., Zhang Z., Raitskin O., et al. Heterogeneous nuclear ribonucleoprotein G regulates splice site selection by binding to CC(A/C)-rich regions in pre-mRNA. J Biol Chem 2009, 284(21):14303-14315. http://dx.doi.org/10.1074/jbc.M901026200.
114. Hastings M.L., Allemand E., Duelli D.M., Myers M.P., Krainer A.R. Control of pre-mRNA splicing by the general splicing factors PUF60 and U2AF(65). PLoS One 2007, 2(6):e538. http://dx.doi.org/10.1371/journal.pone.0000538.
115. Buratti E., Baralle F.E. Influence of RNA secondary structure on the pre-mRNA splicing process. Mol Cell Biol 2004, 24(24):10505-10514. http://dx.doi.org/10.1128/MCB.24.24.10505-10514.2004.
116. Graveley B.R. Mutually exclusive splicing of the insect Dscam pre-mRNA directed by competing intronic RNA secondary structures. Cell 2005, 123(1):65-73. http://dx.doi.org/10.1016/j.cell.2005.07.028.
117. Shepard P.J., Hertel K.J. Conserved RNA secondary structures promote alternative splicing. RNA 2008, 14(8):1463-1469. http://dx.doi.org/10.1261/rna.1069408.
118. Warf M.B., Berglund J.A. Role of RNA structure in regulating pre-mRNA splicing. Trends Biochem Sci 2010, 35(3):169-178. http://dx.doi.org/10.1016/j.tibs.2009.10.004.
119. Gralla J., Crothers D.M. Free energy of imperfect nucleic acid helices. II. Small hairpin loops. J Mol Biol 1973, 73(4):497-511.
120. Pörschke D. Model calculations on the kinetics of oligonucleotide double helix coil transitions. Evidence for a fast chain sliding reaction. Biophys Chem 1974, 2(2):83-96.
121. Darzacq X., Shav-Tal Y., de Turris V., et al. In vivo dynamics of RNA polymerase II transcription. Nat Struct Mol Biol 2007, 14(9):796-806. http://dx.doi.org/10.1038/nsmb1280.
122. Thapar R., Denmon A.P., Nikonowicz E.P. Recognition modes of RNA tetraloops and tetraloop-like motifs by RNA-binding proteins. Wiley Interdiscip Rev RNA 2014, 5(1):49-67. http://dx.doi.org/10.1002/wrna.1196.
123. Wilkinson K.A., Merino E.J., Weeks K.M. Selective 2'-hydroxyl acylation analyzed by primer extension (SHAPE): quantitative RNA structure analysis at single nucleotide resolution. Nat Protoc 2006, 1(3):1610-1616. http://dx.doi.org/10.1038/nprot.2006.249.
124. Martins de Araújo M., Bonnal S., Hastings M.L., Krainer A.R., Valcárcel J. Differential 3' splice site recognition of SMN1 and SMN2 transcripts by U2AF and U2 snRNP. RNA 2009, 15(4):515-523. http://dx.doi.org/10.1261/rna.1273209.
125. Cho S., Moon H., Loh T.J., et al. Splicing inhibition of U2AF65 leads to alternative exon skipping. Proc Natl Acad Sci USA 2015, 112(32):9926-9931. http://dx.doi.org/10.1073/pnas.1500639112.
126. Huelga S.C., Vu A.Q., Arnold J.D., et al. Integrative genome-wide analysis reveals cooperative regulation of alternative splicing by hnRNP proteins. Cell Rep 2012, 1(2):167-178. http://dx.doi.org/10.1016/j.celrep.2012.02.001.
127. Novoyatleva T., Heinrich B., Tang Y., et al. Protein phosphatase 1 binds to the RNA recognition motif of several splicing factors and regulates alternative pre-mRNA processing. Hum Mol Genet 2008, 17(1):52-70. http://dx.doi.org/10.1093/hmg/ddm284.
128. Zhang Z., Kelemen O., van Santen M.A., et al. Synthesis and characterization of pseudocantharidins, novel phosphatase modulators that promote the inclusion of exon 7 into the SMN (survival of motoneuron) pre-mRNA. J Biol Chem 2011, 286(12):10126-10136. http://dx.doi.org/10.1074/jbc.M110.183970.
129. Khan D.H., Gonzalez C., Cooper C., et al. RNA-dependent dynamic histone acetylation regulates MCL1 alternative splicing. Nucleic Acids Res 2014, 42(3):1656-1670. http://dx.doi.org/10.1093/nar/gkt1134.
130. Germain-Desprez D., Brun T., Rochette C., Semionov A., Rouget R., Simard L.R. The SMN genes are subject to transcriptional regulation during cellular differentiation. Gene 2001, 279(2):109-117.
131. Monani U.R., McPherson J.D., Burghes A.H. Promoter analysis of the human centromeric and telomeric survival motor neuron genes (SMNC and SMNT). Biochim Biophys Acta 1999, 1445(3):330-336.
132. Echaniz-Laguna A., Miniou P., Bartholdi D., Melki J. The promoters of the survival motor neuron gene (SMN) and its copy (SMNc) share common regulatory elements. Am J Hum Genet 1999, 64(5):1365-1370. http://dx.doi.org/10.1086/302372.
133. Branchu J., Biondi O., Chali F., et al. Shift from extracellular signal-regulated kinase to AKT/cAMP response element-binding protein pathway increases survival-motor-neuron expression in spinal-muscular-atrophy-like mice and patient cells. J Neurosci 2013, 33(10):4280-4294. http://dx.doi.org/10.1523/JNEUROSCI.2728-12.2013.
134. Boda B., Mas C., Giudicelli C., et al. Survival motor neuron SMN1 and SMN2 gene promoters: identical sequences and differential expression in neurons and non-neuronal cells. Eur J Hum Genet 2004, 12(9):729-737. http://dx.doi.org/10.1038/sj.ejhg.5201217.
135. Majumder S., Varadharaj S., Ghoshal K., Monani U., Burghes A.H.M., Jacob S.T. Identification of a novel cyclic AMP-response element (CRE-II) and the role of CREB-1 in the cAMP-induced expression of the survival motor neuron (SMN) gene. J Biol Chem 2004, 279(15):14803-14811. http://dx.doi.org/10.1074/jbc.M308225200.
136. Altarejos J.Y., Montminy M. CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nat Rev Mol Cell Biol 2011, 12(3):141-151. http://dx.doi.org/10.1038/nrm3072.
137. Rouget R., Vigneault F., Codio C., et al. Characterization of the survival motor neuron (SMN) promoter provides evidence for complex combinatorial regulation in undifferentiated and differentiated P19 cells. Biochem J 2005, 385(Pt 2):433-443. http://dx.doi.org/10.1042/BJ20041024.
138. Katan-Khaykovich Y., Struhl K. Dynamics of global histone acetylation and deacetylation in vivo: rapid restoration of normal histone acetylation status upon removal of activators and repressors. Genes Dev 2002, 16(6):743-752. http://dx.doi.org/10.1101/gad.967302.
139. Sumner C.J., Huynh T.N., Markowitz J.A., et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol 2003, 54(5):647-654. http://dx.doi.org/10.1002/ana.10743.
140. Brichta L., Hofmann Y., Hahnen E., et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 2003, 12(19):2481-2489. http://dx.doi.org/10.1093/hmg/ddg256.
141. Andreassi C., Angelozzi C., Tiziano F.D., et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet 2004, 12(1):59-65. http://dx.doi.org/10.1038/sj.ejhg.5201102.
142. Acuña L.I.G., Kornblihtt A.R. Long range chromatin organization: a new layer in splicing regulation?. Transcription 2014, 5(3):e28726. http://dx.doi.org/10.4161/trns.28726.
143. Dujardin G., Lafaille C., de la Mata M., et al. How slow RNA polymerase II elongation favors alternative exon skipping. Mol Cell 2014, 54(4):683-690. http://dx.doi.org/10.1016/j.molcel.2014.03.044.
144. Martinez-Contreras R., Fisette J.-F., Nasim F.H., Madden R., Cordeau M., Chabot B. Intronic binding sites for hnRNP A/B and hnRNP F/H proteins stimulate pre-mRNA splicing. PLoS Biol 2006, 4(2):e21. http://dx.doi.org/10.1371/journal.pbio.0040021.
145. Lemieux B., Blanchette M., Monette A., Mouland A.J., Wellinger R.J., Chabot B. A function for the hnRNP a1/A2 proteins in transcription elongation. PLoS One 2015, 10(5):e0126654. http://dx.doi.org/10.1371/journal.pone.0126654.
146. Tsai L.-K., Tsai M.-S., Lin T.-B., Hwu W.-L., Li H. Establishing a standardized therapeutic testing protocol for spinal muscular atrophy. Neurobiol Dis 2006, 24(2):286-295. http://dx.doi.org/10.1016/j.nbd.2006.07.004.
147. Tsai L.-K., Tsai M.-S., Ting C.-H., Li H. Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice. J Mol Med 2008, 86(11):1243-1254. http://dx.doi.org/10.1007/s00109-008-0388-1.
148. Narver H.L., Kong L., Burnett B.G., et al. Sustained improvement of spinal muscular atrophy mice treated with trichostatin A plus nutrition. Ann Neurol 2008, 64(4):465-470. http://dx.doi.org/10.1002/ana.21449.
149. Heier C.R., Satta R., Lutz C., DiDonato C.J. Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice. Hum Mol Genet 2010, 19(20):3906-3918. http://dx.doi.org/10.1093/hmg/ddq330.
150. Liu H., Yazdani A., Murray L.M., Beauvais A., Kothary R. The Smn-independent beneficial effects of trichostatin A on an intermediate mouse model of spinal muscular atrophy. PLoS One 2014, 9(7):e101225. http://dx.doi.org/10.1371/journal.pone.0101225.
151. Somers E., Riessland M., Schreml J., Wirth B., Gillingwater T.H., Parson S.H. Increasing SMN levels using the histone deacetylase inhibitor SAHA ameliorates defects in skeletal muscle microvasculature in a mouse model of severe spinal muscular atrophy. Neurosci Lett 2013, 544:100-104. http://dx.doi.org/10.1016/j.neulet.2013.03.052.
152. Schreml J., Riessland M., Paterno M., et al. Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585. Eur J Hum Genet 2013, 21(6):643-652. http://dx.doi.org/10.1038/ejhg.2012.222.
153. Butchbach M.E.R., Singh J., Thorsteinsdóttir M., et al. Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Hum Mol Genet 2010, 19(3):454-467. http://dx.doi.org/10.1093/hmg/ddp510.
154. Butchbach M.E.R., Rose F.F., Rhoades S., et al. Effect of diet on the survival and phenotype of a mouse model for spinal muscular atrophy. Biochem Biophys Res Commun 2010, 391(1):835-840. http://dx.doi.org/10.1016/j.bbrc.2009.11.148.
155. Butchbach M.E.R., Singh J., Gurney M.E., Burghes A.H.M. The effect of diet on the protective action of D156844 observed in spinal muscular atrophy mice. Exp Neurol 2014, 256:1-6. http://dx.doi.org/10.1016/j.expneurol.2014.03.005.
156. Harris A.W., Butchbach M.E.R. The effect of the DcpS inhibitor D156844 on the protective action of follistatin in mice with spinal muscular atrophy. Neuromuscul Disord May 2015, http://dx.doi.org/10.1016/j.nmd.2015.05.008.
157. Cherry J.J., Osman E.Y., Evans M.C., et al. Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds. EMBO Mol Med 2013, 5(7):1103-1118. http://dx.doi.org/10.1002/emmm.201202305.
158. Farooq F., Molina F.A., Hadwen J., et al. Prolactin increases SMN expression and survival in a mouse model of severe spinal muscular atrophy via the STAT5 pathway. J Clin Invest 2011, 121(8):3042-3050. http://dx.doi.org/10.1172/JCI46276.
159. Farooq F., Abadía-Molina F., Mackenzie D., et al. Celecoxib increases SMN and survival in a severe spinal muscular atrophy mouse model via p38 pathway activation. Hum Mol Genet May 2013, http://dx.doi.org/10.1093/hmg/ddt191.
160. Hadwen J., MacKenzie D., Shamim F., et al. VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models. Orphanet J Rare Dis 2014, 9:4. http://dx.doi.org/10.1186/1750-1172-9-4.
161. Liu H.-C., Ting C.-H., Wen H.-L., et al. Sodium vanadate combined with L-ascorbic acid delays disease progression, enhances motor performance, and ameliorates muscle atrophy and weakness in mice with spinal muscular atrophy. BMC Med 2013, 11:38. http://dx.doi.org/10.1186/1741-7015-11-38.
162. Jarecki J., Chen X., Bernardino A., et al. Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Hum Mol Genet 2005, 14(14):2003-2018. http://dx.doi.org/10.1093/hmg/ddi205.
163. Gogliotti R.G., Cardona H., Singh J., et al. The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models. Hum Mol Genet 2013, 22(20):4084-4101. http://dx.doi.org/10.1093/hmg/ddt258.
164. Naryshkin N.A., Weetall M., Dakka A., et al. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science 2014, 345(6197):688-693. http://dx.doi.org/10.1126/science.1250127.
165. Turner B.J., Parkinson N.J., Davies K.E., Talbot K. Survival motor neuron deficiency enhances progression in an amyotrophic lateral sclerosis mouse model. Neurobiol Dis 2009, 34(3):511-517. http://dx.doi.org/10.1016/j.nbd.2009.03.005.
166. Sun S., Ling S.-C., Qiu J., et al. ALS-causative mutations in FUS/TLS confer gain and loss of function by altered association with SMN and U1-snRNP. Nat Commun 2015, 6:6171. http://dx.doi.org/10.1038/ncomms7171.
167. Yu Y., Chi B., Xia W., et al. U1 snRNP is mislocalized in ALS patient fibroblasts bearing NLS mutations in FUS and is required for motor neuron outgrowth in zebrafish. Nucleic Acids Res 2015, 43(6):3208-3218. http://dx.doi.org/10.1093/nar/gkv157.
168. Ottesen E.W., Howell M.D., Singh N.N., Seo J., Whitley E.M., Singh R.N. Severe impairment of male reproductive organ development in a low SMN expressing mouse model of spinal muscular atrophy. Sci Rep 2016, 6:20193. http://dx.doi.org/10.1038/srep20193.
169. Seo J., Singh N.N., Ottesen E.W., Sivanesan S., Shishimorova M., Singh R.N. Oxidative stress triggers body-wide skipping of multiple exons of spinal muscular atrophy gene. PLoS One 2016, 11(4):e0154390. http://dx.doi.org/10.1371/journal.pone.0154390.
170. Seo J., Singh N.N., Ottesen E.W., Lee B.M., Singh R.N. A novel human-specific splice isoform alters the critical C-terminus of survival motor neuron protein. Sci Rep 2016, 6:30778. http://dx.doi.org/10.1038/srep30778.